Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12771636.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic fungal infections have high mortality, and therapy is often toxic. Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a better alternative to typical therapy for Candida krusei. Case report. Multidisciplinary intensive care unit (ICU) of a community teaching hospital. A 22-yr-old male with acute lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphotericin B. Caspofungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with standard ICU care. Survival without toxicity from therapy. Efficacy of caspofungin acetate in a patient with life-threatening Candida Krusei infection.
Medical subject headings
- Anti-Bacterial Agents
- Antifungal Agents
- Candidiasis
- Fungemia
- Opportunistic Infections
- Peptides
- Peptides, Cyclic
- Pleural Effusion